Difficulties to take a decision for treatment because the drugs recommended in guidelines are not reimbursed by the insurance company

When guideline-recommended drugs are not reimbursed by the insurance, the clinicians face significant challenges in treatment decision-making....

Calitatea vieții pacienţilor cu cancer în timpul tratamentului oncologic activ şi în cadrul îngrijirilor paliative

Acest scurt review analizează definiția şi măsurarea calității vieții pacienților oncologici, atât în cursul terapiei active anti­tu­mo­rale, cât şi în timpul îngrijirilor paliative....

Lung cancer news

We have selected some news of the last two months related to lung cancer, published online in Medscape, Cancer Connect and IASLC....

Integrating quality of life into clinical practice

The European Society for Medical Oncology (ESMO) defines survivorship as follows: “survivorship focuses on health and the physical, psychological, social and economic issues affecting people after the end of the primary treatment for cancer”(1)....

Inflammatory myofibroblastic tumor – case report

, , , Victor Strâmbu,

Tumorile miofibroblastice inflamatorii se înscriu în categoria patologiilor rare, cu afectarea predominantă a copiilor şi adulţilor tineri....

2024: ten years of progress in EGFRm NSCLC

Cancerul pulmonar rămâne principala cauză a deceselor de­­ter­­­mi­­na­­te de cancer la nivel global, cancerul pulmonar cu ce­lu­le non-mici (NSCLC) fiind cel mai prevalent subtip. ...

Palliative care as a specialty or a subspeciality (competence)?

Palliative care is explicitly recognized under the human right to health. It should be provided through person-centered and integrated health services that pay special attention to the specific needs and preferences of individuals(1). ...

Palliative care at the end of life, according to main medicine societies of the world

În acest review, am reprodus principalele recomandări ale celor mai importante societăţi medicale din întreaga lume privind îngrijirile paliative, în special la sfârşitul vieţii....

ESMO news – May 2024

In medical oncology, the deepening understanding of the mechanisms of cancer cell development has determined the appearance of a very large number of drugs involved in various mechanisms of cancer cell proliferation....

The importance of publications in non-ISI journals

The objective analysis of ISI (Web of Science) journals reveals, in addition to benefits, some shortcomings that disadvantage some valuable authors....

Some important trials regarding the digestive cancers presented at ASCO and ESMO congresses with impact in current medical practice

Acest scurt review se referă la principalele studii prezentate la congresele ASCO şi ESMO din 2023, având ca subiect cancerele digestive. Din analiza acestor studii rezultă că chimioterapia, în specia...

Analysis of abstracts sent to the 2023 Congress of the National Society of Medical Oncology

Acest review include o analiză sumară a rezumatelor trimise la Congresul Societăţii Naţionale de Oncologie Medicală din anul 2023. Astfel, din cele 49 de rezumate trimise, 26 au fost prezentări de caz, 12 au fost review-uri şi 11 lucrări originale. Impresia generală este că, la aproximativ 700 de medici on­co...

A new and important finding about the immunotherapy of metastatic non-small cell lung cancer

Recently, the researchers have obviously sought for the introduction of immunotherapy alone or in combination and after the failure of a first-line immunotherapy. Novel treatment approaches are needed to overcome innate and acquired mechanisms of resistance to current anticancer therapies in cancer cells and ...

Ultrasonography in necrotic choroidal melanoma

, , , Alina Ciocâlteu,

Melanomul uveal este cea mai frecventă tumoră malignă in­tra­oculară la adulţi, cu originea în tractul uveal al glo­bu­lui ocular. Necroza spontană a melanoamelor coroidale este foarte rară, dar unele melanoame uveale pot fi pre­di­spuse la necroză spontană, din cauza creşterii rapide. Diagnosticul unui melan...

Ethics in medical scientific societies

This topic is almost never addressed by those involved or by some external observatories. In this short review of the problem, I want to bring arguments for two important problems: the internal organization of scientific medical societies and the sponsorships of pharmaceutical companies. They are very importa...

Real-world evidence with nivolumab in advanced non-small cell lung cancer – second line and beyond. Our experience in Romania following straightaway reimbursement of healthcare costs

,

Neoplasmul pulmonar reprezintă principala cauză a mor­ta­li­tă­ţii prin cancer la nivel mondial, ocupând locul al doilea în statisticile de incidenţă globală. Managementul te­­ra­­peu­­tic al can­ce­...